Janux Therapeutics is a pre-commercial biotech with a platform-first strategy, evidenced by R&D expenses averaging $30M per quarter against sporadic collaboration revenue that swung from $10.3M in 2026Q2 to zero in 2025Q1. The company's $928M equity base and m...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.35-39.3% vs -$0.25 | $10M-46.2% vs $19M |
Q2 2026 May 7, 2026 | -$0.39+25.0% vs -$0.52 | $4M-14.3% vs $4M |
Q1 2026 Feb 26, 2026 | -$0.51+21.5% vs -$0.65 | $8M+9356.0% vs $83,333 |
Q4 2025 Nov 6, 2025 | -$0.39+35.0% vs -$0.60 | $10M vs — |
Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX), a clinical-stage biotechnology company developing tumor-activated immunotherapies, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating JANX013, Janux's novel PSMA-targeted tumor-activated CD28 co-stimulatory bispecific, in patients with metastatic castration-resistant prostate cancer (mCRPC). The program is initially being developed in combination with JANX007, with the goal of furthe.
Wall Street analysts reshuffled the deck on Monday with a wave of upgrades, downgrades, and fresh initiations spanning pharma giants, fast-casual chains, and streaming players. Find out which names got bullish bets and which lost their analyst backing.
Janux stock climbs 19.1% in three months as pipeline progress, upcoming catalysts and a strong cash position boost investor confidence.
Benchmark JANX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Janux Therapeutics, Inc. (JANX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $16.52 | $1.01B | -9.03 | -5.55% | -1136.25% | -11.48% | — | |
| $34.54 | $7.13B | -12.47 | — | -7585.86% | -69.59% | — | |
| $115.47 | $9.5B | -31.29 | -16.72% | -285.41% | -21.5% | — | |
| $26.39 | $3.32B | -8.02 | -4.26% | -386.32% | -87.98% | — | |
| $24.45 | $3.98B | -28.10 | 48.29% | -229.92% | -25.74% | — | |
| $190.74 | $40.55B | -32.06 | — | — | -96.44% | — |
Janux Therapeutics, Inc. (JANX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Janux Therapeutics, Inc. (JANX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 23, 2026·SEC
Jun 12, 2026·SEC
Get notified when JANX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Janux Therapeutics, Inc. (JANX) stock FAQ — growth, dividends, profitability & financials explained
Janux Therapeutics, Inc. (JANX) reported $31.9M in revenue for fiscal year 2025.
Janux Therapeutics, Inc. (JANX) saw revenue decline by 5.6% over the past year.
Janux Therapeutics, Inc. (JANX) reported a net loss of $102.6M for fiscal year 2025.
Janux Therapeutics, Inc. (JANX) has a return on equity (ROE) of -11.5%. Negative ROE indicates the company is unprofitable.
Janux Therapeutics, Inc. (JANX) had negative free cash flow of $54.5M in fiscal year 2025, likely due to heavy capital investments.
